Harmony Biosciences Holdings Inc (NASDAQ: HRMY) kicked off on Monday, up 3.62% from the previous trading day, before settling in for the closing price of $34.50. Over the past 52 weeks, HRMY has traded in a range of $19.03-$40.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 546.41%. While this was happening, its average annual earnings per share was recorded 4.36%. With a float of $30.67 million, this company’s outstanding shares have now reached $56.77 million.
Considering the fact that the conglomerate employs 246 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 77.6%, operating margin of 27.14%, and the pretax margin is 25.15%.
Harmony Biosciences Holdings Inc (HRMY) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Harmony Biosciences Holdings Inc is 46.03%, while institutional ownership is 65.00%. The most recent insider transaction that took place on Oct 03 ’24, was worth 532,163. Before that another transaction happened on Oct 01 ’24, when Company’s CHIEF COMMERCIAL OFFICER sold 400 for $40.19, making the entire transaction worth $16,077. This insider now owns 0 shares in total.
Harmony Biosciences Holdings Inc (HRMY) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 4.36% per share during the next fiscal year.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Trading Performance Indicators
Take a look at Harmony Biosciences Holdings Inc’s (HRMY) current performance indicators. Last quarter, stock had a quick ratio of 3.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.10. Likewise, its price to free cash flow for the trailing twelve months is 9.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.95, a number that is poised to hit 0.66 in the next quarter and is forecasted to reach 3.26 in one year’s time.
Technical Analysis of Harmony Biosciences Holdings Inc (HRMY)
Compared to the last year’s volume of 0.41 million, its volume of 0.49 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 47.01%. Additionally, its Average True Range was 1.17.
During the past 100 days, Harmony Biosciences Holdings Inc’s (HRMY) raw stochastic average was set at 59.68%, which indicates a significant decrease from 84.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.04% in the past 14 days, which was lower than the 39.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.39, while its 200-day Moving Average is $32.73. Nevertheless, the first resistance level for the watch stands at $36.16 in the near term. At $36.56, the stock is likely to face the second major resistance level. The third major resistance level sits at $37.33. If the price goes on to break the first support level at $34.99, it is likely to go to the next support level at $34.22. Now, if the price goes above the second support level, the third support stands at $33.82.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Key Stats
The company with the Market Capitalisation of 2.03 billion has total of 56,792K Shares Outstanding. Its annual sales at the moment are 582,020 K in contrast with the sum of 128,850 K annual income. Company’s last quarter sales were recorded 172,810 K and last quarter income was 11,590 K.
